Freedom Capital Downgrades Amgen (NASDAQ:AMGN) to Hold

Amgen (NASDAQ:AMGN) was downgraded by Freedom Capital from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other research analysts also recently issued reports on the stock. The Goldman Sachs Group upped their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Daiwa Securities Group upped their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday. Oppenheimer set a $400.00 target price on Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Citigroup upped their price target on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $354.04.

Amgen Stock Up 0.8%

Shares of NASDAQ:AMGN opened at $369.19 on Thursday. The stock’s 50-day moving average is $337.47 and its 200 day moving average is $313.61. The company has a market cap of $198.80 billion, a PE ratio of 25.94, a P/E/G ratio of 3.75 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen has a 1 year low of $261.43 and a 1 year high of $385.12.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen will post 20.62 EPS for the current year.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amgen

Several large investors have recently made changes to their positions in the business. Brighton Jones LLC grew its holdings in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the last quarter. Angeles Wealth Management LLC grew its holdings in shares of Amgen by 29.2% in the second quarter. Angeles Wealth Management LLC now owns 1,314 shares of the medical research company’s stock valued at $367,000 after purchasing an additional 297 shares in the last quarter. Stratos Wealth Partners LTD. grew its holdings in shares of Amgen by 11.4% in the second quarter. Stratos Wealth Partners LTD. now owns 28,245 shares of the medical research company’s stock valued at $7,886,000 after purchasing an additional 2,899 shares in the last quarter. Finally, Nicholson Wealth Management Group LLC increased its position in Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after purchasing an additional 35 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.